Oncotarget’s Success In Publishing Different Fields Beyond Oncology

Oncotarget is a multidisciplinary traditional journal having free access. The weekly issue publishes papers online. The word “oncology” entails all cellular functions present in cancer and aging, lymphocytes and neurons, microbes and cancer cells. The rising popularity of Oncotarget is informed by its insightful, constructive, punctual and multiple peer-review that helps the authors to increase the impact of their research. Since 2013, four authors that publish their articles through Oncotarget, Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge, won the Breakthrough Prize. View Mikhail’s profile in LinkedIn

Oncotarget’s mission is to make scientific results to be widely available and accessible. In addition, the journal maximizes the impact of research through insightful reviews that enhances the sharing of different discoveries quickly. The management of the journal is seeking to eliminate the boundaries between various specialties. They are also aiming to publish various topics in biomedical science. Most articles have been discussing about the use of clinical science to treat different ailments. Through the leadership of the prominent scientists, the journal has been able to help different researchers to make positive contributions in their respective fields of specialization. Most researchers seek to develop different therapies that can be used to cure different diseases. The success of Oncotarget has resulted in the publication of different topics beyond oncology

Oncotarget was established in 2010. Mikhail Blagosklonny and Andrei V. Gudkov are the editors-in-chief of the revered journal. Mikhail Blagosklonny is a renowned scientist who researches on cancer and aging. He was a professor of oncology at Roswell Park Cancer Institute in New York. Blagosklonny earned both his M.D in internal medicine and PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg. Blagosklonny’s research zeroes in on cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging and anti-aging drugs.

Oncotarget applies the Creative Commons Attribution License to all the works that they publish. Under the CC BY, authors retain ownership of the copyright for their articles. However, they allow anyone to download, reuse, reprint, modify, distribute and copy articles, provided the original authors and sources of information are cited appropriately. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

Comments are closed.